Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775060 | 0.98 | DRD2 (0.42) | DRD2DRD4HTR7DRD3HTR2A | |
| SCHEMBL6775741 | 0.90 | HTR7 (0.41) | DRD2DRD4HTR7DRD3HTR2A | |
| SCHEMBL6769942 | 0.90 | DRD3 (0.41) | DRD2HTR7DRD3HTR2AALDH1A1 | |
| SCHEMBL6773923 | 0.89 | DRD2 (0.41) | DRD2DRD4ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL6776122 | 0.88 | MEN1 (0.41) | DRD2DRD4HTR7DRD3HTR2A | |
| SCHEMBL6653693 | 0.87 | DRD2 (0.43) | DRD2DRD4ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL6780120 | 0.85 | ABCB1 (0.42) | DRD2HTR7DRD3HTR2AHTR2C | |
| SCHEMBL6775556 | 0.85 | HTR1A (0.43) | HTR7DRD3ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL6775985 | 0.83 | DRD3 (0.46) | DRD2DRD4HTR7DRD3HTR2A | |
| SCHEMBL6774683 | 0.82 | DRD3 (0.55) | DRD2DRD4HTR7DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030166926-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2003-09-04 | — | — | US | disclosed |
| US-6489473-B2 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION | SUNTORY LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020072515-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0807632-B1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LTD (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6258805-B1 | TREATMENT OF BRAIN DISORDERS AND HYPERTENSION | SUNTORY LIMITED (JP) | 2001-07-10 | — | — | US | disclosed |
| EP-0807632-A1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072515-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | DRD2 34/4885DRD4 152/4885HTR7 39/4885 |
| US-20030166926-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | DRD2 34/4885DRD4 167/4885HTR7 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.